|
Originally published In Press as doi:10.1074/jbc.M102908200 on June 8, 2001
J. Biol. Chem., Vol. 276, Issue 31, 29051-29058, August 3, 2001
Biochemical Studies of Zmpste24-deficient Mice*
Gordon K.
Leung §¶ ,
Walter K.
Schmidt **,
Martin O.
Bergo § ,
Bryant
Gavino ,
Darren H.
Wong ,
Amy
Tam**,
Matthew N.
Ashby ,
Susan
Michaelis**, and
Stephen G.
Young §¶§§
From the Gladstone Institute of Cardiovascular
Disease, § Cardiovascular Research Institute, and
¶ Department of Medicine, University of California, San
Francisco, California 94141-9100, the ** Department of Cell Biology and
Anatomy, The Johns Hopkins University School of Medicine, Baltimore,
Maryland 21205, and  Axys Pharmaceuticals,
South San Francisco, California 94080
Received for publication, April 3, 2001, and in revised form, June 4, 2001
 |
ABSTRACT |
Genetic studies in Saccharomyces
cerevisiae identified two genes, STE24 and
RCE1, involved in cleaving the three
carboxyl-terminal amino acids from isoprenylated proteins that
terminate with a CAAX sequence motif. Ste24p cleaves the
carboxyl-terminal "-AAX" from the yeast mating
pheromone a-factor, whereas Rce1p cleaves the -AAX
from both a-factor and Ras2p. Ste24p also cleaves the amino terminus of a-factor. The mouse genome contains
orthologues for both yeast RCE1 and STE24. We
previously demonstrated, with a gene-knockout experiment, that mouse
Rce1 is essential for development and that Rce1 is entirely
responsible for the carboxyl-terminal proteolytic processing of the
mouse Ras proteins. In this study, we cloned mouse
Zmpste24, the orthologue for yeast STE24 and
showed that it could promote a-factor production when
expressed in yeast. Then, to assess the importance of
Zmpste24 in development, we generated
Zmpste24-deficient mice. Unlike the Rce1
knockout mice, Zmpste24-deficient mice survived development
and were fertile. Since no natural substrates for mammalian Zmpste24
have been identified, yeast a-factor was used as a
surrogate substrate to investigate the biochemical activities in
membranes from the cells and tissues of Zmpste24-deficient
mice. We demonstrate that Zmpste24-deficient mouse membranes, like
Ste24p-deficient yeast membranes, have diminished CAAX
proteolytic activity and lack the ability to cleave the amino terminus
of the a-factor precursor. Thus, both enzymatic activities of yeast Ste24p are conserved in mouse Zmpste24, but these enzymatic activities are not essential for mouse development or for fertility.
 |
INTRODUCTION |
Proteins that terminate in a carboxyl-terminal CAAX
motif1 undergo three
sequential enzymatic processing events, farnesylation or
geranylgeranylation of the cysteine, endoproteolytic release of the
last three amino acid residues of the protein (i.e. removal of the -AAX), and methylation of the new carboxyl terminus
of the protein by isoprenylcysteine carboxyl methyltransferase (1, 2).
The yeast genes responsible for the farnesylation and methylation steps
were identified more than a decade ago (3, 4), but the identification
of the genes responsible for the middle processing step, the
endoprotease step, remained elusive for years (2). Ultimately, however,
Boyartchuk and co-workers (5) applied a novel genetic selection scheme
and identified two yeast genes, RCE1 and STE24
(AFC1), involved in the carboxyl-terminal endoproteolytic processing of isoprenylated CAAX proteins. Rce1p is a
protease involved in the carboxyl-terminal processing of both
a-factor and the yeast Ras protein, Ras2p. Ste24p (Afc1p), a
zinc metalloprotease, lacked activity against Ras2p but did process
a-factor. Haploid MATa yeast lacking both
RCE1 and STE24 (ste24 rce1 ) grew normally
but were unable to produce mature a-factor and therefore
were sterile (5). Interestingly, Rce1p and Ste24p exhibited subtle
differences in substrate specificities (5-7). Both proteins were
capable of cleaving the carboxyl terminus of wild-type
a-factor, which terminates in CVIA. However, only Ste24p
processed an a-factor mutant terminating in CAMQ, and only
Rce1p processed an a-factor mutant terminating in
CTLM.2
The identification of Ste24p as a CAAX endoprotease was
initially surprising because Ste24p had also been described as a
protease that cleaves the amino terminus of the a-factor
precursor protein (8), and it seemed improbable that a single protease would recognize and cleave a single protein at two completely different
sites. Subsequent studies, however, established that Ste24p does indeed
play dual roles in a-factor processing (6, 9). In addition
to being a CAAX endoprotease, Ste24p removes the seven
amino-terminal amino acids from the a-factor precursor.
Ste24 is, however, only the first of two proteases that cleave the
amino terminus of a-factor. After the Ste24p-mediated cleavage step, an additional cleavage by Axl1p releases mature biologically active a-factor.
When the two CAAX endoproteases were identified in yeast,
apparent orthologues already existed in mammalian cDNA data bases. Tam and co-workers (9) obtained a full-length cDNA for human ZMPSTE24, the orthologue for yeast STE24, and
showed that its amino acid sequence was 36% identical to the yeast
protein. No a-factor orthologue has been discovered in
mammals, and no natural substrates for human ZMPSTE24 have been
identified. However, the human enzyme faithfully carried out both the
amino-terminal and carboxyl-terminal processing of a surrogate
substrate, yeast a-factor, and restored a-factor
production in MATa ste24 rce1 yeast (9,
10).
Our laboratory has sought to define the physiologic importance of the
mammalian CAAX endoproteases, as well as the CAAX
methyltransferase, isoprenylcysteine carboxyl methyltransferase
(ICMT). We cloned and expressed cDNAs for human and mouse
Rce1 and showed that the mammalian Rce1 proteins processed
the Ras proteins as well as several other CAAX proteins (11,
12). Rce1 knockout mice died during embryonic development
(11). However, studies with Rce1-deficient embryos and
embryonic fibroblasts showed that Rce1 is essential for Ras
processing (11). Like Rce1, ICMT is essential for the processing of
mammalian CAAX proteins and also for survival during embryonic development (13).
In the current study, we have turned our attention to cloning mouse
Zmpste24 and producing Zmpste24-deficient mice.
When we initiated this project, we had several physiologic and
biochemical issues in mind. First, we wanted to gauge the physiologic
importance of Zmpste24 in mammals. Would
Zmpste24 be required for embryonic development, as
was the case for Rce1 and ICMT? If
Zmpste24-deficient mice survived, would they be fertile?
From the biochemical perspective, we wanted to determine whether mouse
Zmpste24 would be capable of carrying out the carboxyl-terminal
processing of a-factor and, if so, whether the mouse enzyme
would manifest the same peculiar specificities as the yeast enzyme
(e.g. the ability to cleave an a-factor mutant
terminating in CAMQ). We also wanted to determine whether the mouse
enzyme would cleave the amino terminus of yeast a-factor
and, if so, whether this enzymatic activity would be present in
detectable levels in the tissues of wild-type mice. Finally, we wanted
to determine if mouse Zmpste24 was the only mammalian enzyme
capable of carrying out the amino-terminal processing of
a-factor, or whether mammalian cells might contain more than
one enzyme with that activity. Our current studies provide insights
into each of these issues.
 |
EXPERIMENTAL PROCEDURES |
A Mouse Zmpste24 cDNA Clone--
A XREFdb query (14) of
GenBankTM sequences with yeast STE24 sequences
identified a human expressed sequence tag with sequence similarities
(I.M.A.G.E. clone 284572, Research Genetics, Huntsville, AL).
Oligonucleotide primers 5'-GAGTTTCAAGCTGATGCATTTGC-3' and 5'-GAGTTTCAAGCTGATGCATTGC-3' derived from the human sequence were used
to amplify a 382-base pair (bp) fragment (representing sequences from
Zmpste24 exons 9 and 10) from a mouse liver cDNA
library. The 5' portion of the mouse Zmpste24 cDNA was
generated by 5' rapid amplification of cDNA ends with
oligonucleotide 5'-AGTCTTTAGCCTTCCCAAGTTTCTTGGC-3' (corresponding to
Zmpste24 amino acids 422-430) and the Marathon-Ready mouse liver
cDNA kit (CLONTECH, Palo Alto, CA).
Oligonucleotides 5'-ACTCTCCGAGGGACGCGTGT-3' and
5'-CTTAAGAGCATCCAGTCATG-3' were used to amplify a mouse
Zmpste24 cDNA. The cDNA was cloned into a TOPO
TA cloning vector (Invitrogen, Carlsblad, CA), and both strands
were sequenced. Predicted transmembrane domains were determined with
the TMHMM transmembrane domain analysis program
(genome.cbs.dtu.dk/services/TMHMM-1.0/). Amino acid sequences from
different species were aligned with MacVector 6.5.
Expression of Zmpste24 in different mouse tissues was
assessed by hybridizing a 32P-labeled Zmpste24
cDNA probe to a mouse Multiple Choice Northern blot (OriGene
Technologies, Rockville, MD) and to a mouse multiple-tissue poly(A)+ RNA blot (CLONTECH).
Hybridization and washing were performed as described previously (12).
The blots were exposed to x-ray film for 72 h at 80 °C.
Yeast Strains and Methods--
JRY5314
MATa his3-11 leu2-3,112 trp1
ura3-1; JRY5315 ste24 ::HIS3;
JRY5316 rce1 ::TRP1; JRY5317
ste24 ::HIS3
rce1 ::TRP1; JRY5463
MATa
mfa1::hisG
mfa2::hisG ura3 leu2 his3 trp1 ste24 ::HIS3
rce1 ::TRP1; and JRY3443
MAT trp1 ura1 his3
sst2-4oc were provided by Dr. Jasper Rine (University
of California, Berkeley). Each of the JRY strains was isogenic. SM3614
MATa trp1 leu2 ura3 his4 can1
ste24::LEU2 rce1::TRP1
pSM1317 was used as a source of methyltransferase (9, 15). SM1086
MAT sst2-1 rme his6 met1 can1 cyh2
was also used for halo assays to score a-factor production
(3, 16). SM3103 MATa trp1 leu2 ura3 his4
can1 ste24::LEU2 pSM219 was used to prepare a
P1 a-factor intermediate (4, 8, 10). Yeast strains were
grown and maintained by standard methods (16, 17).
Yeast Expression Vectors for Endoproteases--
Expression
plasmids for mouse Zmpste24 (pMB4), yeast STE24
(pMB5), yeast RCE1 (pMB6), and mouse Rce1 (pMB7)
were created in the vector pMB1. To produce pMB1, the yeast shuttle
vector Yeplac195 (18) was modified by inserting an
ADH2 promoter and a PGK1 transcriptional terminator into the polylinker. The ADH2 promoter (579 bp
upstream of the translational start site) was amplified from W303-1a
genomic DNA with oligonucleotides
5'-CAGCTATGACCATGATTACGCCAAGCTTCAAAGGGGCAAAACGTAGGGGCAA-3' and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCTAGACATTGTGTATTACGATATAGTTAATAG-3'. The PGK1 transcriptional termination sequence (478 bp
downstream from the PGK1 translational stop codon) was
amplified with oligonucleotides 5'-CTATTAACTATATCGTAATACACAATGTCTAGATAAATTGAATTGAATTGAAATCGATAGATCAA-3' and 5'-CGTTGTAAAACGACGGCCAGTGAATTCATATGTCTCTGAATGCCAAGGATGG-3'. pMB1 was assembled by recombination in yeast (19) by transforming yeast strain W303-1a with the ADH2 and PGK1 PCR
products and Yeplac195 that had been linearized with
HindIII and EcoRI.
All expression vectors were created by recombinational cloning after
co-transformation of XbaI-cleaved pMB1 and PCR-amplified endoprotease open reading frames. A mouse Zmpste24
open reading frame was amplified with oligonucleotides
5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3' and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3'. A
mutant Zmpste24 cDNA (pMB9) was also constructed; the
mutant lacks the sequences from the 104-bp exon 8, which encodes the zinc-binding HEXXH motif (HEXXH: H, histidine; E,
glutamate; X, any amino acid). For this mutant, two
fragments of the mouse Zmpste24 cDNA (corresponding to
amino acids 1-318 and 354-475) were amplified from Marathon Ready
mouse liver cDNA (CLONTECH) with
oligonucleotides 5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3',
5'-CTATTAACTATATCGTAATACACAATGGGGATGTGGGCATCGGTGGAC-3', and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3' and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGTCTTGTTTTGCATTTTTCAGAGC-3'. To
construct pMB5, a yeast STE24 (YJR117W) open reading frame was amplified from W303-1a genomic DNA with oligonucleotides
5'-CAACTATTAACTATATCGTAATACACAATGTTTGATCTTAAGACGATTCTCG-3' and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATTAGTTTTTCTTCTTTTCACTAACATAG-3'. To
construct pMB6, the yeast RCE1 (YMR274C) open reading frame was PCR amplified from W303-1a genomic DNA with oligonucleotides 5'-CAACTATTAACTATATCGTAATACACAATGCTACAATTCTCAACATTTCTAG-3' and 5'-TTGATCTATCGATTTCAATTCAATTCAATTTACTAAAGGGTTATTCTATAACCAGGAGTT-3'. A
mouse Rce1 open reading frame was PCR amplified from
Marathon Ready mouse liver cDNA (CLONTECH) with
oligonucleotides
5'-CAACTATTAACTATATCGTAATACACAATGTCTGTGTTCTCCTGCTTCAGCCTCGCC-3' and
5'-TTGATCTATCGATTTCAATTCAATTCAATTTATCAGGAGCACAGTAGGGTCTCTGAG-3'.
Documenting That Mouse Zmpste24 Processes Yeast
a-Factor--
To test the expression vectors (pMB4, pMB5,
pMB6, pMB7, pMB8, and pMB9), each was transformed into
MATa ste24 rce1 yeast (JRY5317).
The ability of each expression vector to restore a-factor
production was assessed with a standard pheromone diffusion (halo)
assay (7). The principle underlying the halo assay is that the
production of mature a-factor by a
MATa yeast strain results in a zone of growth
inhibition (halo) on a lawn of MAT sst2 cells.
Analyzing the Substrate Specificity of Mammalian Endoproteases
with Halo Assays--
The coding regions of human Rce1 and
mouse Zmpste24 were amplified by PCR, as described earlier,
and cloned into pACA1 (5). Site-directed mutagenesis was used to change
the CVIA CAAX box in the a-factor gene
(MFA1) to CAMQ or CTLM. The mutant a-factor
plasmids were transformed into a MATa
ste24 rce1 mfa1 mfa2 strain (JRY5463) (6).
Yeast strains expressing the a-factor mutants and either
human RCE1 or mouse Zmpste24 were spotted onto a
lawn MAT sst2 cells (JRY3443) and allowed to
grow for 2 days at 30 °C. The production of mature
a-factor from a mutant a-factor construct was
evident from a halo in the lawn of MAT sst2 cells.
Analyzing the Substrate Specificity of Mammalian Endoproteases
with a Coupled Proteolysis/Methylation Assay--
The ability of yeast
and mouse endoproteases to process 15-mer a-factor peptides
terminating in CAMQ or CVIA was assessed in a coupled
proteolysis/methylation assay (5, 11, 12). A wild-type CVIA
a-factor peptide (YIIKGVFWDPA[farnesyl-C]VIA) and a mutant
CAMQ a-factor peptide (YIIKGVFWDPA[farnesyl-C]AMQ) were
purchased from California Peptide Research (Napa, CA). Membrane fractions were prepared from ste24 rce1 yeast (JRY5317)
that had been transformed with pMB4, pMB5, pMB6, pMB7, or pMB9. Yeast membranes (100 µg) were mixed with 4 nmol of peptide and 10 µM S-adenosyl-L-[methyl-14C]methionine
(55 Ci/mol, Amersham Pharmacia Biotech, Piscataway, NJ) and incubated
for 120 min at 37 °C. The methylation reaction was stopped by adding
50 µl of 1.0 M NaOH containing 0.1% SDS. The reaction
mixture (90 µl) was spotted onto a pleated 2 × 8-cm filter
paper wedged in the neck of a 20-ml scintillation vial containing 5 ml
of scintillation fluid (ScintiSafe Econo 1, Fisher). The vials were
capped and incubated at room temperature for 5 h to allow the
[14C]methanol (formed by base-hydrolysis of methyl
esters) to diffuse into the scintillation fluid (20-22).
Construction of a Zmpste24 Gene-Targeting Vector--
The
screening of a strain 129/Sv bacterial artificial chromosome (BAC)
library (Research Genetics) with the 382-bp cDNA fragment resulted
in the identification a BAC clone (223 G6) that contained the 3'
portion of mouse Zmpste24. A 9.4-kb SpeI fragment
containing Zmpste24 exons 7-9 was subcloned into pBSSK
(Stratagene, La Jolla, CA). These sequences were used to construct a
sequence-replacement gene-targeting vector in pKSLoxPNT
(23). pKSLoxPNT contains polylinker cloning sites, a
thymidine kinase (tk) gene, and a 3-phosphoglycerate
kinase-neomycin resistance (PGK-neo) cassette flanked by
loxP sites. The long arm (4.6 kb of intron sequences 5' to
exon 8) was amplified from BAC DNA with oligonucleotides 5'-CAAGTGATTCGAGGCTAGCCTGGTCTACG-3' and
5'-GGCCTTGACCCATCTAATCAAACAACCAGAC-3' and the Expand Long Template PCR
System (Roche Molecular Biochemicals, Indianapolis, IN). The PCR
fragment was cloned into the EcoRI site of
pKSLoxPNT. The short arm (2.6 kb of intron sequences 3' to
exon 8) was amplified with oligonucleotides
5'-ACGACGGCGGCCGCGAAACTGGCCTGGTGTTCACTATGTAGC-3' and
5'-AGCAGCGCGGCCGCGAGGGCACAACACTGTATGTTACCAGG-3' and cloned into
the NotI site. The integrity of the vector was verified by restriction mapping and DNA sequencing. The vector was linearized with
XhoI before the electroporation of mouse embryonic stem (ES) cells.
Generation of Zmpste24-deficient Mice--
Mouse ES cells
(strain 129/SvJae) (24) were cultured on mitomycin C-treated STO feeder
cells in high-glucose Dulbecco's modified Eagle's medium supplemented
with 15% ES cell-grade fetal bovine serum, 2 mM
L-glutamine, 6 mM HEPES, 100 units/ml
penicillin, 100 µg/ml streptomycin, 1 × nonessential amino
acids (Hyclone, Logan, UT), 0.14 mM 2-mercaptoethanol
(Sigma), and 1000 units/ml leukemia inhibitory factor (Life
Technologies, Rockville, MD). G418 (final concentration, 200 µg/ml)
was added to the medium 24 h after the electroporation.
1-(2'Deoxy-2'fluoro- -D-arabinofuranosyl)-5-iodouracil (final concentration, 0.2 µM) was added to the medium for
4 days, beginning 3 days after the electroporation. Drug-resistant ES cell colonies were picked 10 days after the electroporation, and targeted clones (Zmpste24+/ ) were identified by Southern
blotting of EcoRI-digested ES cell DNA with a 441-bp
5'-flanking probe (see Fig. 1A). The 5' probe, which was
amplified from BAC DNA with oligonucleotides
5'-CCCACAACTGTGGACTTTGATGGATCAGG-3' and 5'-GGTATGCACCACCTTCCCCTGACTACT-3', detects an 8.0-kb EcoRI
fragment in wild-type (Zmpste24+/+) cells. Targeted cells
(Zmpste24+/ ) were identified by the presence of
a 5.0-kb fragment in addition to the 8.0-kb fragment. Targeted clones
were also screened by digesting genomic DNA with SpeI and
then performing a Southern blot with a 388-bp 3'-flanking probe (see
Fig. 1A). The 3' probe was amplified from BAC DNA with
oligonucleotides 5'-CTAGACTCTTTGGGGTAGTG-3' and
5'-ACGACGGCGGCCGCGGCTTAGTGGGTCCTGGAAGGAACTTTA-3'. The 3' probe detects a 9.4-kb SpeI fragment in Zmpste24+/+
cells; Zmpste24+/ cells contained a 4.3-kb fragment in
addition to the 9.4-kb fragment.
Two targeted clones, each with a single neo integration,
were used to generate Zmpste24-deficient mice (25). All mice
had a mixed genetic background (~50% C57BL/6 and ~50% 129/Sv).
The mice were weaned at 21 days of age, housed in a barrier facility with 12-h light/dark cycle, and fed a chow diet containing 4.5% fat
(Ralston Purina, St. Louis, MO). All mice described herein were
examined at 8-12 weeks of age. Zmpste24 / ,
Zmpste24+/ , and Zmpste24+/+ embryonic
fibroblasts were prepared from 13.5-day mouse embryos (11).
Production of Chimeric Mice from Zmpste24 / ES
Cells--
Homozygous knockout cells (Zmpste24 / ) were
isolated as described by Mortensen et al. (26). Two lines of
Zmpste24 / ES cells were injected into C57BL/6
blastocysts to generate chimeric mice. At 8 weeks of age, the chimeric
mice were sacrificed, and genomic DNA from multiple tissues was
analyzed with Southern blots with the 5' probe.
Bioassays to Assess Carboxyl-terminal Processing of an
a-Factor Peptide by Membranes from Mouse Cells and
Tissues--
The ability of Zmpste24 /
membranes to cleave the carboxyl terminus of an a-factor
peptide, generating mature a-factor, was assessed with a
bioassay.3 Membranes from
tissues of Zmpste24+/+ and Zmpste24 / mice and from Zmpste24+/+ and Zmpste24 / cells were
mechanically disrupted by sonication (Branson sonifier, 10 cycles,
output = 5, duty cycle = 50%) in an ice-cold hypotonic lysis
buffer (10 mM Tris-HCl, 1 mM MgCl2,
1 µM dithiothreitol, pH 7.4 containing protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 2 µg/ml
aprotinin, and 3 µg/ml leupeptin, chymostatin, and pepstatin). The
samples were then homogenized on ice with a Dounce homogenizer,
resuspended in 0.15 M NaCl, and then subjected to
centrifugation at 4 °C for 3000 × g for 10 min. The
pellet was discarded and the supernatant fluid was spun at 100,000 × g for 30 min at 4 °C. The supernatant fluid was
discarded and the pellet, representing the membrane fraction, was
resuspended in ice-cold buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, and protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 3 µg/ml
leupeptin, chymostatin, and pepstatin)) at concentrations of 3-14
mg/ml and then frozen at 80 °C. A 100 µM solution of the CAMQ peptide was prepared in methanol. Membranes from
ste24 rce1 yeast that expressed STE14 from a
2-µm plasmid (SM3614/pSM1317) were prepared as a source of the
prenylprotein methyltransferase (15). Each carboxyl-terminal processing
reaction contained the a-factor peptide (0.75 µM), membranes from mouse tissues (75 µg/ml),
ste24 rce1 /Ste14p yeast membranes (0.1 mg/ml) in a
buffer containing 75 mM HEPES, 75 mM NaCl, 15 mM EDTA, pH 7.5, and 20 µM
S-adenosyl-L-methionine. The reactions were
assembled in 96-well polystyrene plates in a total volume of 25 µl.
After a 2-h incubation at 30 °C, the reactions were terminated by
adding copper acetate (final concentration, 2 mM). The
production of mature a-factor was detected by plating
dilutions of the reaction mixture on a lawn of MAT
sst2 cells (SM1086) and allowing the cells to grow for 2 days at 30 °C (27, 28).3 Mature a-factor
results in a zone of growth inhibition in the lawn of cells.
Assessing the Ability of Mouse Membranes to Carry Out the
Amino-terminal Processing of P1 a-Factor--
Yeast
membranes containing radiolabeled P1 a-factor were prepared
as previously described (10). P1 a-factor is fully
COOH-terminal modified (i.e. isoprenylated, cleaved, and
carboxyl methylated) (29). In a wild-type strain, COOH-terminal processing of a-factor occurs first and is followed by NH2-terminal processing (29). Isoprenylation is required
(29) for the production of P1 a-factor, but blocking either methylation (30) or CAAX
processing4 does not impede
NH2-terminal processing. Briefly, a yeast strain lacking
STE24 but expressing MFA1 from a high-copy
plasmid (SM3103/pSM219) was radiolabeled with
[35S]cysteine, and membranes containing P1
a-factor were isolated (10). Proteolysis reactions
(typically 50 µl) were assembled on ice in polystyrene 96-well
plates. Each reaction contained the metabolically labeled yeast
membranes (0.5 mg/ml) and membranes (0.5 mg/ml) from
Zmpste24+/+ or Zmpste24 / cells or tissues in a buffer containing 100 mM HEPES and 100 mM
NaCl, pH 7.5. Some of the reaction mixtures contained 2 mM
1,10-phenanthroline, a zinc chelator. After a 2-h incubation at
30 °C, reactions were terminated by adding 1% SDS and heating the
samples to 100 °C for 3 min. The a-factor intermediates
were immunoprecipitated with an a-factor-specific antiserum.
Each immunoprecipitate was then size-fractionated by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and analyzed with a PhosphorImager (10,
29).
Assessing the Accumulation of "Methylatable" Substrates in
Rce1-, ICMT-, and Zmpste24-deficient Fibroblasts--
Whole cell
extracts (150 µg) from primary fibroblasts (Zmpste24+/+,
Zmpste24 / , ICMT+/+, ICMT / ,
Rce1+/+, and Rce1 / ) (11, 13) were incubated
with 10 µM
S-adenosyl-L-[methyl-14C]methionine
(55 Ci/mol, Amersham Pharmacia Biotech), Sf9 cells expressing high levels of Ste14p (100 µg), yeast membranes expressing high levels of mouse Rce1 (100 µg), and yeast membranes
containing high levels of mouse Zmpste24 (100 µg). The
reaction was incubated for 2 h at 37 °C, and the levels of
methylatable substrates in the wild-type and knockout cell extracts
were compared with the base hydrolysis/methanol diffusion assay.
We also incubated whole cell extracts from Rce1+/+ and
Rce1 / fibroblasts in the presence of yeast membranes
containing high levels of mouse Rce1 or yeast membranes containing high
levels of mouse Zmpste24. All incubations contained 10 µM
S-adenosyl-L-[methyl-14C]methionine
and Escherichia coli membranes containing high levels of
yeast Ste14p (4). The reactions were incubated for 2 h at 37 °C, and the levels of methylatable substrates in the cell
extracts were compared with the base hydrolysis/methanol diffusion
assay. All incubations were performed in duplicate.
 |
RESULTS |
A Mouse Zmpste24 cDNA--
DNA sequencing of a mouse
Zmpste24 cDNA revealed that the mouse enzyme, like the
human enzyme, contains 475 amino acids (Fig. 1). The mouse and human amino acid
sequences were 93% identical. Both the mouse and human sequences were
36% identical to the S. cerevisiae Ste24p sequence, with
the highest levels of similarity within the last third of the molecule.
Mouse Zmpste24, like the human and yeast enzymes, has a
HEXXH motif (residues 335-339) that is characteristic of
zinc metalloproteinases (5, 8, 9) and multiple membrane-spanning
domains (Fig. 1). Mouse Zmpste24 is expressed in multiple
tissues, with the highest levels of expression in the liver and kidney
(Fig. 2).

View larger version (78K):
[in this window]
[in a new window]
|
Fig. 1.
The mouse Zmpste24 amino
acid sequence, aligned with the human and yeast sequences. A
conserved HEXXH zinc-binding motif is present in each of the
three sequences (residues 335-339 of the mouse and human sequence).
The mouse sequence is predicted to contain multiple transmembrane
domains (residues 19-37, 80-102, 121-143, 171-189, 198-216,
349-367, and 386-408). The yeast and human sequences also are
predicted to contain multiple transmembrane domains (2).
GenBankTM for mouse Zmpste24 cDNA sequence:
AY029194.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 2.
Northern blot showing Zmpste24
expression in multiple mouse tissues. A
32P-labeled Zmpste24 cDNA probe was
hybridized to a mouse Multiple Choice Northern blot (OriGene). Loading
of samples was normalized to -actin. The blot was exposed to x-ray
film for 72 h at 80 °C. A similar pattern was observed with a
multiple tissue poly(A)+ RNA blot from
CLONTECH (not shown).
|
|
Functional Studies of Mouse Zmpste24 in Yeast--
To assess the
functional integrity of mouse Zmpste24, a yeast plasmid
encoding the Zmpste24 cDNA was transformed into
ste24 rce1 yeast. The transformed cells were tested for
the ability to produce a-factor with an established bioassay
that utilizes a lawn of MAT sst2 cells.
Nontransformed ste24 rce1 yeast do not produce a zone
of growth inhibition (halo) on the lawn of MAT
sst2 cells since they cannot form mature
a-factor. The plasmid encoding mouse Zmpste24
restored a-factor production, as judged by the halo
surrounding the colony (Fig.
3A). Mouse Rce1
also restored a-factor production (Fig. 3A). In
anticipation of performing a gene-targeting experiment in mice, we
sought to establish that the removal of the 104-bp exon 8 of
Zmpste24 (encoding amino acids 318-354, containing the
HEXXH motif) would inactivate the gene product. We therefore
transformed the ste24 rce1 yeast with a mutant mouse
Zmpste24 cDNA lacking exon 8 sequences. The mutant
cDNA did not restore a-factor production (Fig.
3A).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 3.
Yeast halo assays demonstrating that mouse
Zmpste24 complements the defect in
a-factor production in ste24 rce1
yeast. A, halo assay demonstrating that the
expression of yeast RCE1 (from plasmid pMB6), mouse
Rce1 (pMB7), yeast STE24 (pMB5), and mouse
Zmpste24 (pMB4) restores the production of
a-factor in ste24 rce1 yeast (JRY5317
ste24 ::HIS3
rce1 ::TRP1). A mutant mouse
Zmpste24 construct lacking exon 8 sequences (which encode
the HEXXH motif) did not restore a-factor
production. B, halo assay demonstrating that yeast
expressing mouse Zmpste24 process a mutant
a-factor terminating in CAMQ (halo marked by
arrows) but not a mutant terminating in CTLM (absent
halo). Yeast expressing mouse Rce1 process a mutant
a-factor terminating in CTLM (halo marked by
arrows) but not a mutant terminating in CAMQ (absent
halo). The halos in Panel B are smaller than in
Panel A because detergents were not included in the agar in
Panel B. C, coupled endoproteolysis/methylation
assay demonstrating that the CAMQ a-factor peptide is
cleaved and methylated by membranes from ste24 rce1
yeast (JRY5317) that overexpress mouse Zmpste24 or yeast
STE24 but not by membranes that overexpress yeast
RCE1, mouse Rce1, or the mutant mouse
Zmpste24. D, coupled endoproteolysis/methylation
assay demonstrating that the CVIA a-factor peptide is
cleaved and methylated by membranes from ste24 rce1
yeast that express mouse Zmpste24, yeast STE24,
mouse Rce1, and yeast RCE1, but not by the mutant
mouse Zmpste24.
|
|
Boyartchuk and co-workers (6) demonstrated that yeast Ste24p and Rce1p
have distinct specificities for a-factor precursors with
different CAAX sequences. Both yeast Ste24p and yeast Rce1p
processed the wild-type a-factor precursor, which terminates
in CVIA (5, 6). Ste24p was uniquely capable of processing mutant
a-factor precursor molecules terminating in CAMQ, while
Rce1p was uniquely capable of cleaving a mutant a-factor
terminating in CTLM. Interestingly, we found that the mammalian enzymes
exhibited the same specificities. Both mouse Rce1 and mouse Zmpste24
were capable of processing the wild-type a-factor
terminating in CVIA (Fig. 3A). However, only RCE1 processed
a mutant a-factor terminating in CTLM, and only Zmpste24
processed a mutant a-factor terminating in CAMQ (Fig.
3B).
The fact that both yeast Ste24p and mouse Zmpste24 can cleave a CAMQ
a-factor was confirmed with coupled
endoproteolysis/methylation assays (Fig. 3C). Membranes from
ste24 rce1 yeast that overexpressed yeast
STE24 or mouse Zmpste24 cleaved and methylated a
CAMQ a-factor peptide. Yeast membranes overexpressing the
mutant mouse Zmpste24 (lacking the HEXXH motif) did not
methylate the peptide, nor did yeast membranes that overexpressed yeast
Rce1p or mouse Rce1. In contrast, membranes from yeast expressing
mouse Zmpste24, yeast STE24, mouse
Rce1, and yeast RCE1 cleaved and then methylated the wild-type CVIA a-factor peptide (Fig.
3D).
Zmpste24 Knockout Mice--
A gene-targeting vector designed to
replace exon 8 of Zmpste24 with a neo was used to
inactivate mouse Zmpste24 (Fig.
4A). Approximately 1 in 30 drug-resistant clones was targeted (Fig. 4B). Two ES cell
lines were used to generate Zmpste24+/ mice, which were
bred to generate Zmpste24 / mice (Fig. 4C).
Zmpste24 / mice (produced from both targeted ES cell
clones) were born at the expected mendelian frequency and were viable
and fertile. To assess the relative capacities of wild-type cells and
Zmpste24 / cells to contribute to the formation of
different mouse tissues, chimeric mice were generated with
Zmpste24 / ES cells (Fig. 4D). A total of 12 high-percentage (>90%) chimeric mice were obtained. As judged by
Southern blot analysis, the Zmpste24-deficient ES cells
contributed robustly to the formation of each tissue that was analyzed
(heart, lung, liver, spleen, kidney, adipose, brain, intestine, skin,
testes, and skeletal muscle) (not shown).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 4.
Inactivating the mouse Zmpste24
gene. A, sequence-replacement gene-targeting
vector designed to replace Zmpste24 exon 8 with a
neo. Mouse exons were numbered according to corresponding
exons in the human gene sequence (BAC clone RP1-39G22,
GenBankTM AL05034). B, Southern blots
identifying gene-targeting events in mouse ES cells. C,
Southern blot identification of 4-week-old
Zmpste24+/+, Zmpste24+/ , and
Zmpste24 / mice with the 5'-flanking probe. D,
Southern blot demonstrating the production of Zmpste24 /
ES cells. The Zmpste24 / cells were generated by growing
Zmpste24+/ in high concentrations of G418, as described by
Mortensen et al. (26). The genomic DNA was digested with
EcoRI, and the blot was hybridized with the 5'-flanking
probe.
|
|
Assessing Zmpste24 Enzymatic Activity Levels--
We next sought
to determine if the targeted mutation in Zmpste24 / mice
was associated with detectable changes in enzymatic activity levels.
Since no natural substrates for mammalian Zmpste24 have been
described, we tested the possibility that the membranes from
Zmpste24 / cells and tissues would be deficient in their capacity to process a surrogate substrate, yeast a-factor. In the first series of experiments, we incubated
Zmpste24 / and Zmpste24+/+ membranes
with the CAMQ a-factor peptide in the presence of
S-adenosyl-L-[methyl-14C]methionine,
and then assessed base-labile methylation of the peptide. Similar
levels of methylation were observed with both Zmpste24 /
and Zmpste24+/+ membranes (Zmpste24+/+, 0.82 ± 0.02 pmol/mg/min; Zmpste24 / 0.78 ± 0.02 pmol/mg/min), and the methylation was sensitive to 1,10-phenanthroline
(data not shown). This result was clearly different from what we
observed with the coupled endoprotease/methylation assays involving
yeast membranes; Zmpste24-containing yeast membranes processed the CAMQ
a-factor peptide significantly more than membranes lacking
Zmpste24 (see Fig. 3C).
We suspected that the failure to find differences in methylation
of the CAMQ a-factor peptide by Zmpste24 / and
Zmpste24+/+ membranes was due to the
presence of a membrane-bound, phenanthroline-sensitive exoprotease in
the mouse membranes, which would be expected to generate
farnesylcysteines or short farnesylcysteine-containing peptides. The
latter substances would be readily methylated and would increase the
background in the experiment, making it impossible to detect potential
differences between the ability of Zmpste24 / and Zmpste24+/+ membranes to carry out the carboxyl-terminal
endoproteolytic processing of a-factor. To circumvent this
problem, we decided to perform a more specific assay, a yeast bioassay
for fully processed mature a-factor. In this assay, we
tested whether membranes from Zmpste24-deficient cells and
tissues would be defective in producing mature a-factor from
the 15-mer CAMQ a-factor peptide (i.e. defective
in cleaving the -AMQ from the peptide, making it a substrate for
carboxyl methylation). To address this issue, the CAMQ
a-factor peptide was mixed with mouse liver membranes for
2 h, and the production of a-factor was assessed by
assessing the ability of mature a-factor to inhibit the
growth of MAT sst2 yeast. Notably, membranes
from livers of Zmpste24 / mice were 4-8 times less
efficient in producing mature a-factor (Fig.
5A). Similar results were
observed in other tissues in an independent experiment (Fig.
5B).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 5.
Reduced carboxyl-terminal processing of a
CAMQ a-factor peptide by membranes prepared from
livers of Zmpste24 / mice.
A, a CAMQ a-factor peptide was mixed with
Zmpste24 / or Zmpste24+/+ liver membranes (75 µg/ml) and incubated for 2 h at 30 °C. Incubations were
performed in the presence and absence of 1,10-phenanthroline. Serial
dilutions of the samples were plated on a lawn of MAT
sst2 yeast cells (SM1086); the production of mature
a-factor was judged by inhibition of yeast growth. There was
some residual activity in Zmpste24 / membranes, which
could be largely blocked with 1,10-phenanthroline. The residual
activity was probably not due to Rce1 because Rce1 activity is not
affected significantly by 1,10-phenanthroline (33) and because Rce1
cannot process a CAMQ a-factor peptide. B,
independent experiment testing the capacity of membranes from different
Zmpste24 / or Zmpste24+/+ tissues to generate
mature a-factor from the same CAMQ
a-factor.
|
|
We also examined the possibility that membranes from
Zmpste24 / cells and tissues would be deficient
in their ability to cleave the amino terminus of an a-factor
intermediate. In yeast, both in vivo and in
vitro, Ste24p cleaves the seven amino-terminal amino acids from P1
(farnesylated a-factor precursor), generating a shorter
intermediate, P2, which can be resolved from P1 by SDS-PAGE (9, 10,
29). We produced a metabolically labeled P1 intermediate in
ste24 yeast, then tested the ability of
Zmpste24 / and Zmpste24+/+ membranes to cleave the amino terminus from P1, converting it to P2 (Fig.
6). Membranes from Zmpste24+/+
ES cells and fibroblasts converted P1 to P2, and this activity was
blocked by 1,10-phenanthroline (Fig. 6A). Membranes from
Zmpste24 / ES cells and fibroblasts lacked this activity
(Fig. 6A). Similarly, membranes from the liver, heart, and
skeletal muscle of Zmpste24+/+ mice converted P1
to P2, whereas membranes from Zmpste24 / mice did not
(Fig. 6B).

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 6.
Reduced ability of membranes from
Zmpste24 / cells and tissues to carry out the
amino-terminal processing of a-factor. An
35S-labeled P1 a-factor intermediate was
prepared from a yeast strain that lacked STE24 and expressed
MFA1 from a high-copy plasmid. Proteolysis reactions were
performed by incubating the radiolabeled P1 with mouse membranes for
2 h at 30 °C in the absence or presence of 1,10-phenanthroline.
The a-factor intermediates were then immunoprecipitated with
an a-factor-specific antiserum and size-fractionated by
SDS-PAGE. Dried gels were analyzed by autoradiography and with a
PhosphorImager. The amino-terminal processing reaction cleaves seven
amino acids from the amino terminus of P1, yielding the shorter
intermediate P2 (9, 29). A, ability of membranes from ES
cells and fibroblasts to cleave the P1 a-factor
intermediate. B, ability of membranes from
Zmpste24-deficient mouse tissues to cleave the P1
a-factor intermediate.
|
|
Testing for the Accumulation of Substrates in Rce1 / and
Zmpste24 / Cells--
Although no natural Zmpste24 CAAX
protein substrates have been identified, the high degree of sequence
conservation in the enzyme suggests that natural substrates must exist.
We hypothesized that significant amounts of CAAX protein
substrates might accumulate in both Rce1-deficient cells and
Zmpste24-deficient cells. To test that possibility, whole
cell extracts from primary fibroblasts (Zmpste24+/+, Zmpste24 / ,
Rce1+/+, and Rce1 / ) were incubated with
S-adenosyl-L-[methyl-14C]methionine
and membranes containing high levels of Ste14p, mouse Rce1, and mouse
Zmpste24. As a control, we examined the accumulation of protein
substrates in whole cell extracts from ICMT+/+ and ICMT / fibroblasts (13). The accumulation of methylatable
substrates in each extract was gauged with a base hydrolysis/methanol
diffusion assay. As expected, methylatable substrates accumulated in
ICMT / cells (Fig.
7A). Substrates also
accumulated in Rce1 / cells (Fig. 7A).
However, no such accumulation was detectable in
Zmpste24 / cells (Fig. 7A). Similarly, no
accumulation of methylatable substrates was detected in extracts of
Zmpste24 / livers, kidneys, or hearts (not shown).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
Absence of a detectable accumulation of
"methylatable" substrates in Zmpste24 /
cells. A, methylation of whole cell extracts from
primary fibroblasts derived from Zmpste24+/+,
Zmpste24 / , ICMT+/+,
ICMT / , Rce1+/+, and Rce1 /
embryos. The cell extracts were incubated with
S-adenosyl-L-[methyl-14C]methionine,
membranes containing high levels of Ste14p, yeast membranes containing
high levels of mouse Rce1, and yeast membranes containing high levels
of mouse Zmpste24. The relative level of methylatable substrates in
wild-type and knockout cells was assessed with a base
hydrolysis/methanol diffusion assay. For the Zmpste24+/+ and
Zmpste24 / cells, we observed identical results when
membranes expressing Rce1 were left out of the reaction mixture.
B, methylation of whole cell extracts from
Rce1+/+ and Rce1 / fibroblasts in the presence
of yeast membranes containing high levels of mouse Rce1 or membranes
containing high levels of mouse Zmpste24. In these experiments, we
demonstrated that the yeast membranes contained active Zmpste24 by
showing that they promoted the processing and methylation of the 15-mer
CAMQ a-factor substrate, as shown in Fig.
3D.
|
|
In a separate experiment, we asked whether Zmpste24 would be capable of
processing some or all of the substrates that accumulate in
Rce1-deficient cells. Whole cell extracts from
Rce1+/+ and Rce1 / fibroblasts were incubated
with Ste14p,
S-adenosyl-L-[methyl-14C]methionine,
and either mouse Rce1 or mouse Zmpste24. Again, we noted increased
methylation when Rce1 was added to extracts from
Rce1-deficient cells, reflecting the accumulation of Rce1 substrates in those cells (Fig. 7B). No such increase was
observed when Zmpste24 was added to the Rce1-deficient cell
extracts (Fig. 7B), indicating that Zmpste24 has little
ability to process Rce1 substrates.
 |
DISCUSSION |
We have sought to define the physiologic importance of the two
endoproteases and the methyltransferase involved in the
"post-isoprenylation" processing of proteins containing a
CAAX motif (2). We have shown that ICMT and
Rce1 are essential for the processing of the Ras proteins
and that both are required for embryonic development. The involvement
of Rce1 and ICMT in Ras protein processing was not particularly surprising, given that the corresponding yeast genes,
RCE1 and STE14, had already been shown to be
involved in the processing of yeast Ras2p (4, 5, 31, 32). The fact that
knockouts of the two mouse genes yielded lethal developmental phenotypes was also not too surprising given that both are involved in
the processing of dozens of isoprenylated proteins. In the current
studies, we focused on mouse Zmpste24, the "other"
CAAX endoprotease and arguably the most mysterious and
intriguing of the three post-isoprenylation protein-processing enzymes.
In yeast, the only known substrate for Ste24p is the mating pheromone
a-factor (2, 5, 6, 8-10, 29). Although no
a-factor orthologue has yet been identified in mammals, zinc
metalloproteases similar to Ste24p can be readily identified in many
species throughout the plant and animal kingdoms (2, 9). Interestingly,
the level of amino acid sequence identity is higher for yeast Ste24p
and mouse Zmpste24 than for yeast Rce1p/mouse Rce1 or for yeast Ste14p
and mouse ICMT (2). The high level of sequence similarity initially led
us to suspect that Zmpste24 might also encode a key
housekeeping protein required for mouse survival. This suspicion was
not borne out. Zmpste24-deficient mice developed normally
and were fertile. The absence of a lethal phenotype cannot be
attributed to a leaky phenotype or a poorly designed knockout
experiment. Our gene-targeting vector eliminated the critical
HEXXH zinc-binding domain and introduced a frameshift, and
we had proven with yeast expression studies, even before embarking on
the mouse experiments, that the mutation inactivated the enzyme.
In assessing the biochemical phenotype associated with mouse
Zmpste24 deficiency, we used yeast a-factor as a
surrogate substrate, since no natural mammalian substrates for Zmpste24 have been identified. Nonetheless, our biochemical studies uncovered new and intriguing findings. First, we found that an enzymatic activity
capable of cleaving the amino terminus of a-factor is
expressed at readily detectable levels in wild-type mouse ES cells and
in multiple tissues of wild-type mice. This enzymatic activity was
absent in the setting of Zmpste24 deficiency. Thus, Zmpste24
was the only mammalian enzyme capable of processing the amino terminus of a-factor in vitro; no redundant
"Ste24p/Zmpste24-like" amino-terminal cleavage activities were
detected. We also demonstrated that Zmpste24-deficient cells
are deficient in a specific CAAX endoprotease activity, the
ability to cleave the -AAX from a CAMQ a-factor
peptide. The use of a CAMQ a-factor peptide was essential
for these experiments because it cannot be cleaved by Rce1 (5, 6).
One possible conclusion from the phenotype of the
Zmpste24 / mice is that there are simply
no essential Zmpste24 substrates. Alternatively, developmentally
essential Zmpste24 substrates may exist but are processed, at least to
a degree, by other proteases. In this regard, it is worthwhile pointing
out that STE24-deficient yeast are not completely deficient
in their ability to produce mature a-factor (2, 5, 6, 9).
Some mature a-factor is produced because the carboxyl
terminus of a-factor precursor can be cleaved by Rce1p and
because the Axl1p-mediated amino-terminal cleavage step proceeds,
albeit inefficiently, in the absence of Ste24p. Thus, it is quite
conceivable that the viability of Zmpste24 / mice results
from processing of Zmpste24 substrates by other enzymes.
The only known Ste24p substrate in yeast, a-factor, is
methylated after the proteolytic release of the carboxyl-terminal tripeptide (4). If unique Zmpste24 CAAX protein substrates were to exist in mammalian cells (i.e. substrates not
cleaved by Rce1), we predicted that we would be able to document an
accumulation of methylatable substrates in
Zmpste24-deficient cells. This prediction was not upheld. No
accumulation of methylatable substrates was detected either in
Zmpste24 / ES cells or in a variety of
Zmpste24 / tissues. In contrast, an accumulation of
methylatable substrates was easily detectable in both
Rce1-deficient cells and ICMT-deficient cells.
Recombinant Zmpste24 could not cleave the accumulated substrates in
Rce1 knockout cells. How should these studies be
interpreted? One could properly conclude that these studies show that a
greater number of methylatable protein substrates accumulate in the
setting of Rce1 or ICMT deficiency than in
Zmpste24 deficiency. One could also conclude that Zmpste24
cannot process the uncleaved substrates in Rce1-deficient
cells. However, we would be reluctant to conclude that mammalian cells
have no unique Zmpste24 CAAX protein substrates or that all
Zmpste24 substrates are cleaved by other enzymes
(e.g. Rce1). Unique Zmpste24 substrates may accumulate in
Zmpste24 deficiency but at concentrations too low to yield levels of
carboxyl methylation above background.
The conservation in the enzymatic specificities for yeast Ste24p and
mouse Zmpste24 is remarkable. Mouse Zmpste24 as well as the human
enzyme faithfully cleave the amino terminus of yeast a-factor. Moreover, both mouse Zmpste24 and yeast Ste24p share the property of being able to cleave the carboxyl terminus of a
wild-type a-factor and a CAMQ a-factor mutant, but not a CTLM a-factor mutant. The striking conservation of
Ste24p/Zmpste24 specificities makes it tempting to speculate that an
a-factor orthologue is lurking in the mammalian genome. We
have not yet identified such a protein, but recognizing an open reading
frame as short as 36 amino acids (the length of the a-factor
precursor) could be quite challenging. This challenge is compounded
when one considers the fact that a-factor-like CAAX proteins from diverse organisms (e.g.
Saccharomyces cerevisiae, Schizosaccharomyces pombe,
Ustilago maydis, Ustilago hordei, Filobasidiella neoformans)
exhibit only limited sequence similarities.
 |
ACKNOWLEDGEMENTS |
We thank J. Rine for sharing yeast strains;
S. Clarke for E. coli membranes containing high levels of
yeast Ste14p; and P. Casey, S. Ordway, and G. Howard for criticisms of
the manuscript.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants HL41633 and AG15451 (to S. G. Y.) and GM41223
(to S. M.), a Howard Hughes Medical Institute Postdoctoral
Fellowship for Physicians (to G. K. L.), and grant awards
from the University of California Tobacco-related Disease Research
Program (to M. O. B. and S. G. Y.).
Contributed equally to the results of this work.
§§
To whom reprint requests should be addressed: Gladstone Institute
of Cardiovascular Disease, P. O. Box 419100, San Francisco, CA
94141-9100. Tel.: 415-695-3774; Fax: 415-285-5632; E-mail: syoung@
gladstone.ucsf.edu.
Published, JBC Papers in Press, June 8, 2001, DOI 10.1074/jbc.M102908200
2
CAMQ is the CAAX sequence in the
-subunit of rabbit muscle phosphorylase kinase; CTLM is the
CAAX sequence in yeast Ste18p.
3
A. Tam, W. K. Schmidt, and S. Michaelis,
manuscript in preparation.
4
W. K. Schmidt and S. Michaelis, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
CAAX
motif, carboxyl-terminal CAAX motif is a cysteine (C), a
pair of aliphatic amino acids (A), and then a final amino acid residue
(X);
bp, base pair;
PCR, polymerase chain reaction;
BAC, bacterial artificial chromosome;
ES, embryonic stem;
kb, kilobase pair(s);
PAGE, polyacrylamide gel electrophoresis.
 |
REFERENCES |
| 1.
|
Casey, P. J.,
and Seabra, M. C.
(1996)
J. Biol. Chem.
271,
5289-5292
|
| 2.
|
Young, S. G.,
Ambroziak, P.,
Kim, E.,
and Clarke, S.
(2000)
in
The Enzymes
(Tamanoi, F.
, and Sigman, D. S., eds), Vol. 21
, pp. 155-213, Academic Press, San Diego
|
| 3.
|
Powers, S.,
Michaelis, S.,
Broek, D.,
Anna-A, S. S.,
Field, J.,
Herskowitz, I.,
and Wigler, M.
(1986)
Cell
47,
413-422
|
| 4.
|
Hrycyna, C. A.,
Sapperstein, S. K.,
Clarke, S.,
and Michaelis, S.
(1991)
EMBO J.
10,
1699-1709
|
| 5.
|
Boyartchuk, V. L.,
Ashby, M. N.,
and Rine, J.
(1997)
Science
275,
1796-1800
|
| 6.
|
Boyartchuk, V. L.,
and Rine, J.
(1998)
Genetics
150,
95-101
|
| 7.
|
Trueblood, C. E.,
Boyartchuk, V. L.,
Picologlou, E. A.,
Rozema, D.,
Poulter, C. D.,
and Rine, J.
(2000)
Mol. Cell. Biol.
20,
4381-4392
|
| 8.
|
Fujimura-Kamada, K.,
Nouvet, F. J.,
and Michaelis, S.
(1997)
J. Cell Biol.
136,
271-285
|
| 9.
|
Tam, A.,
Nouvet, F. J.,
Fujimura-Kamada, K.,
Slunt, H.,
Sisodia, S. S.,
and Michaelis, S.
(1998)
J. Cell Biol.
142,
635-649
|
| 10.
|
Schmidt, W. K.,
Tam, A.,
and Michaelis, S.
(2000)
J. Biol. Chem.
275,
6227-6233
|
| 11.
|
Kim, E.,
Ambroziak, P.,
Otto, J. C.,
Taylor, B.,
Ashby, M.,
Shannon, K.,
Casey, P. J.,
and Young, S. G.
(1999)
J. Biol. Chem.
274,
8383-8390
|
| 12.
|
Otto, J. C.,
Kim, E.,
Young, S. G.,
and Casey, P. J.
(1999)
J. Biol. Chem.
274,
8379-8382
|
| 13.
|
Bergo, M. O.,
Leung, G. K.,
Ambroziak, P.,
Otto, J. C.,
Casey, P. J.,
Gomes, A. Q.,
Seabra, M. C.,
and Young, S. G.
(2001)
J. Biol. Chem.
276,
5841-5845
|
| 14.
|
Ploger, R.,
Zhang, J.,
Bassett, D.,
Reeves, R.,
Hieter, P.,
Bouguski, M.,
and Spencer, F.
(2000)
Nucleic Acids Res.
28,
120-122
|
| 15.
|
Romano, J. D.,
Schmidt, W. K.,
and Michaelis, S.
(1998)
Mol. Biol. Cell
9,
2231-2247
|
| 16.
|
Michaelis, S.,
and Herskowitz, I.
(1988)
Mol. Cell. Biol.
8,
1309-1318
|
| 17.
|
Sherman, F.
(1991)
Methods Enzymol.
194,
3-21
|
| 18.
|
Gietz, R. D.,
and Sugino, A.
(1988)
Gene (Amst.)
74,
527-534
|
| 19.
|
Hudson, H. R., Jr.,
Dawson, E. P.,
Rusjing, K. L.,
Jackson, C. H.,
Lockshon, D.,
Conover, D.,
Lanciault, C.,
Harris, J. R.,
Simmons, S. J.,
Rothstein, R.,
and Fields, S.
(1997)
Genome Res.
7,
1169-1172
|
| 20.
|
Clarke, S.,
Vogel, J. P.,
Deschenes, R. J.,
and Stock, J.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
4643-4647
|
| 21.
|
Kim, E.,
Lowenson, J. D.,
MacLaren, D. C.,
Clarke, S.,
and Young, S. G.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6132-6137
|
| 22.
|
Bergo, M. O.,
Leung, G. K.,
Ambroziak, P.,
Otto, J. C.,
Casey, P. J.,
and Young, S. G.
(2000)
J. Biol. Chem.
275,
17605-17610
|
| 23.
|
Hanks, M.,
Wurst, W.,
Anson-Cartwright, L.,
Auerbach, A. B.,
and Joyner, A. L.
(1995)
Science
269,
679-682
|
| 24.
|
Meiner, V. L.,
Cases, S.,
Myers, H. M.,
Sande, E. R.,
Bellosta, S.,
Schambelan, M.,
Pitas, R. E.,
McGuire, J.,
Herz, J.,
and Farese, R. V., Jr.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14041-14046
|
| 25.
|
Hasty, P.,
Bradley, A.,
Morris, J. H.,
Edmondson, D. G.,
Venuti, J. M.,
Olson, E. N.,
and Klein, W. H.
(1993)
Nature
364,
501-506
|
| 26.
|
Mortensen, R.
(1999)
in
Current Protocols in Molecular Biology
(Ausubel, F. M.
, Brent, R.
, Kingston, R. E.
, Moore, D. D.
, Seidman, J. G.
, Smith, J. A.
, and Struhl, K., eds), Vol. 2
, pp. 9.16.1-9.16.11, John Wiley & Sons, New York
|
| 27.
|
Nijbroek, G. L.,
and Michaelis, S.
(1998)
Methods Enzymol.
292,
193-212
|
| 28.
|
Chan, R. K.,
and Otte, C. A.
(1982)
Mol. Cell. Biol.
2,
11-20
|
| 29.
|
Chen, P.,
Sapperstein, S. K.,
Choi, J. D.,
and Michaelis, S.
(1997)
J. Cell Biol.
136,
251-269
|
| 30.
|
Sapperstein, S.,
Berkower, C.,
and Michaelis, S.
(1994)
Mol. Cell. Biol.
14,
1438-1449
|
| 31.
|
Hrycyna, C. A.,
and Clarke, S.
(1992)
J. Biol. Chem.
267,
10457-10464
|
| 32.
|
Ashby, M. N.
(1998)
Curr. Opin. Lipidol.
9,
99-102
|
| 33.
|
Chen, Y.,
Ma, Y.-T.,
and Rando, R. R.
(1996)
Biochemistry
35,
3227-3237
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Ricardo and R. Lehmann
An ABC Transporter Controls Export of a Drosophila Germ Cell Attractant
Science,
February 13, 2009;
323(5916):
943 - 946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Coffinier, S. E. Hudon, R. Lee, E. A. Farber, C. Nobumori, J. H. Miner, D. A. Andres, H. P. Spielmann, C. A. Hrycyna, L. G. Fong, et al.
A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells
J. Biol. Chem.,
April 11, 2008;
283(15):
9797 - 9804.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Coffinier, S. E. Hudon, E. A. Farber, S. Y. Chang, C. A. Hrycyna, S. G. Young, and L. G. Fong
From the Cover: HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells
PNAS,
August 14, 2007;
104(33):
13432 - 13437.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Kilpatrick and J. D. Hildebrandt
Sequence Dependence and Differential Expression of G{gamma}5 Subunit Isoforms of the Heterotrimeric G Proteins Variably Processed after Prenylation in Mammalian Cells
J. Biol. Chem.,
May 11, 2007;
282(19):
14038 - 14047.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ukekawa, K. Miki, M. Fujii, H. Hirano, and D. Ayusawa
Accumulation of multiple forms of lamin A with down-regulation of FACE-1 suppresses growth in senescent human cells
Genes Cells,
March 1, 2007;
12(3):
397 - 406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Young, M. Meta, S. H. Yang, and L. G. Fong
Prelamin A Farnesylation and Progeroid Syndromes
J. Biol. Chem.,
December 29, 2006;
281(52):
39741 - 39745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Huyer, A. Kistler, F. J. Nouvet, C. M. George, M. L. Boyle, and S. Michaelis
Saccharomyces cerevisiae a-Factor Mutants Reveal Residues Critical for Processing, Activity, and Export.
Eukaryot. Cell,
September 1, 2006;
5(9):
1560 - 1570.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Rusinol and M. S. Sinensky
Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
J. Cell Sci.,
August 15, 2006;
119(Pt 16):
3265 - 3272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. G. Young, L. G. Fong, and S. Michaelis
Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis
J. Lipid Res.,
December 1, 2005;
46(12):
2531 - 2558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Yamashita, R. Kamata, N. Kawagishi, H. Nakanishi, H. Suzuki, T. Sugiura, and K. Waku
Roles of C-Terminal Processing, and Involvement in Transacylation Reaction of Human Group IVC Phospholipase A2 (cPLA2{gamma})
J. Biochem.,
May 1, 2005;
137(5):
557 - 567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Zmpste24-/- Mice
Sci. Aging Knowl. Environ.,
January 12, 2005;
2005(2):
tg1 - tg1.
[Full Text]
|
 |
|

|
 |

|
 |
 
L. G. Fong, J. K. Ng, M. Meta, N. Cote, S. H. Yang, C. L. Stewart, T. Sullivan, A. Burghardt, S. Majumdar, K. Reue, et al.
Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice
PNAS,
December 28, 2004;
101(52):
18111 - 18116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Muchir and H. J. Worman
The Nuclear Envelope and Human Disease
Physiology,
October 1, 2004;
19(5):
309 - 314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O. Bergo, H. D. Lieu, B. J. Gavino, P. Ambroziak, J. C. Otto, P. J. Casey, Q. M. Walker, and S. G. Young
On the Physiological Importance of Endoproteolysis of CAAX Proteins: HEART-SPECIFIC RCE1 KNOCKOUT MICE DEVELOP A LETHAL CARDIOMYOPATHY
J. Biol. Chem.,
February 6, 2004;
279(6):
4729 - 4736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. O. Bergo, B. Gavino, J. Ross, W. K. Schmidt, C. Hong, L. V. Kendall, A. Mohr, M. Meta, H. Genant, Y. Jiang, et al.
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect
PNAS,
October 1, 2002;
99(20):
13049 - 13054.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Bracha, M. Lavy, and S. Yalovsky
The Arabidopsis AtSTE24 Is a CAAX Protease with Broad Substrate Specificity
J. Biol. Chem.,
August 9, 2002;
277(33):
29856 - 29864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tam, W. K. Schmidt, and S. Michaelis
The Multispanning Membrane Protein Ste24p Catalyzes CAAX Proteolysis and NH2-terminal Processing of the Yeast a-Factor Precursor
J. Biol. Chem.,
December 7, 2001;
276(50):
46798 - 46806.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|